Background and objective: Post-transplant malignancy (PTM) is a limiting factor both for
Introduction
Post-transplant malignancy (PTM) is the second to third leading cause of death among KTRs (kidney transplant recipients) after cardiovascular disease and/or infection (1-3).
There is a 3-to 5-fold increased incidence of malignancy among KTRs when compared with the age-and sex-matched general population (3, 4) . The incidence of death from cancer is now increasing and becoming a limiting factor both for graft and patient survival (2, 3, 5-7). Thus, more effective strategies for disease control and prevention of PTM are needed to improve the outcomes of KTRs (8) .
In the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines, an individualized screening plan for PTM is recommended (not graded) (8) .
However, the growth of cancers in transplant recipients is often more rapid than in the general population and the prognosis is poor (9, 10) . This is a significant limitation of disease control with early detection by regular screening and treatment of PTM. Therefore, the most valuable approach to reducing cancer morbidity and mortality should lie in primary prevention. development of, and mortality from, various types of cancer, such as colon, pancreas, lung, prostate, breast, ovary, and non-Hodgkin lymphoma (13) (14) (15) (16) (17) . The pre-transplant serum 25(OH)D level has also been shown to be an important determinant for subsequent development of PTM (18) . These results have been supported by the findings that extrarenal 1α-hydroxylase in various tissues contributes to the local production of 1,25-dihydroxyvitamin D [1, 25(OH) 2 D], the most biologically active vitamin D metabolite (19) , along with a number of experimental studies reporting that 1,25(OH) 2 D induces cell differentiation and apoptosis, inhibits proliferation and angiogenesis, and decreases metastatic potential (20). Thus, both nutritional and active vitamin D compounds are suggested to be potential anticancer therapeutics (21, 22) and are now anticipated as potential chemopreventive agents of PTM in KTRs (15) .
There have been two reports of subanalyses of randomized controlled trials (RCT)
showing a lower incidence of cancer in postmenopausal women receiving nutritional vitamin D and calcium supplementation (23, 24). In addition, oral active vitamin D therapy is associated with reduced mortality from malignancies in hemodialysis patients (25).
However, no study has yet described the effect of active vitamin D compounds (AVDs) as chemopreventive agents against PTM, although they are often prescribed for Here, we hypothesized that AVDs could reduce the incidence of PTM and evaluated their effects in a prospective cohort of ambulatory KTRs.
Methods

Study participants
This study examined a prospective cohort of KTRs at the outpatient department of kidney transplantation in Inoue Hospital, Osaka, Japan. Between August 2007 to May 2008, 262 ambulatory KTRs at more than one year after transplantation were enrolled in the prospective registry and followed up until November 2010. Patients excluded were those with acute kidney injury at enrollment (n = 5), subsequent transplantation (n = 5), active cancer (n = 2), and documented non-adherence (n = 3). Also excluded were patients with a history of parathyroidectomy (n = 15), all of whom had received AVDs for the management of hypocalcemia; those with type 1 diabetes (n = 9), all of whom had not received AVDs;
and those who were pregnant or who wished to become pregnant (n = 4) to whom AVD administration required extra care. As a result, 218 (83.2%) patients were included in this study. Patients were considered lost to follow-up if no contact could be documented for more than 3 months. We continued to follow up of the participants even if they restarted We adhered to the Declaration of Helsinki throughout this study. The ethics committee of Inoue Hospital approved the study protocol, and all of the patients provided written informed consent to participate in all aspects of the study.
Data collection
The primary exposure of interest was baseline AVDs defined as calcitriol and alfacalcidol. None of the patients received falecalcitriol or paricalcitol. We did not prescribe cholecalciferol, ergocalciferol, or calcium bicarbonate for these patients. Other 
25-Hydroxyvitamin D levels
Peripheral blood was collected from each participant at inclusion. Serum samples were isolated and stored at −30°C for later analysis. In August 2011, the samples were sent to Kyowa Medex, Inc. (Sunto, Shizuoka, Japan) and assayed for 25(OH)D using the DiaSorin LIAISON 25-hydroxy OH Vitamin D TOTAL Assay (DiaSorin, Inc., Stillwater, MN), a direct competitive chemiluminescence immunoassay. This assay was shown to be an accurate and precise automated tool for the determination of the serum 25(OH)D levels (29) .
Statistical analysis
Values with normal distribution were expressed as mean ± SD; they were compared using unpaired Student's t-test or one-way analysis of variance (ANOVA). If values were not normally distributed, they were expressed as the median (interquartile range, IQR) and were compared using Mann-Whitney U test or Kruskal-Wallis test. Comparisons for nominal variables among groups were assessed with a χ log-rank test.
Because the frequency of PTM development was not large enough to adjust for the baseline clinical characteristics (30), a propensity score (PS) of having received AVDs was estimated as a data reduction technique using logistic regression with the 26 factors given above. Natural log numerical values transformed in this regression were body mass index, time since transplantation, and dialysis vintage as well as serum levels of creatinine, phosphate, 25(OH)D, and iPTH. The C-index of this model was 0.841. The Cox proportional hazards model to estimate the effect of AVD treatment was stratified according to the PS tertiles, assuming that baseline hazard functions are different. As sensitivity analyses, we used four additional models: (i) adjustment for the logit of the PS(31), (ii) stratification for PS quartiles (31), (iii) optimal matching within the caliper of 25% or 30% of the standard deviation of the logit of the PS in which the maximum AVD user : non-user ratio is 2:1 (32), and (iv) inverse probability weighting (33) . The validities of the proportional hazard assumption and the linearity assumption were checked by adding time-dependent interaction variables and quadratic terms for each of the predictors in the models, respectively. A P value of less than 0.05 for two-sided tests was considered significant, and confidence intervals (CIs) reported are 95% intervals. All analyses were and only 7 sufficient (3.2%) (Figure 1 ). AVD users, compared with non-users, were significantly younger, had higher serum creatinine levels, and had had longer periods since transplantation. In AVD users, the serum iPTH levels were significantly lower and serum 25(OH)D levels were marginally higher than those in non-users. During a median follow-up of 2.9 (IQR, 2.1-3.0) years, four AVD users and four non-users died, and five AVD users and eleven non-users developed PTM. The incidence rates of PTM were 2.1
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(95% CI, 0.9-5.1) /100 patient-years and 3.5 (95% CI, 2.0-6.4) /100 patient-years for AVD users and non-users, respectively. Only one patient was lost to follow-up. Table 2 incidence of PTM in AVD users was significantly lower than in non-users (P = 0.033 by log-rank test) (Figure 2-B) , with a HR of 0.31 (95% CI, 0.10-0.97) ( Table 3 ). All other sensitivity analyses yielded similar results (Table 3) . Further adjustment for natural log transformed serum iPTH, where we found a significant difference between AVD users and non-users within the highest PS tertile, did not affect these results, as expected biologically.
Discussion
In this study, we showed a lower risk of PTM development in KTRs with AVDs using the Cox regression analysis adjusting for the baseline characteristics with stratification by PS tertiles. Among 228 KTRs with a time period since transplantation of over one year, vitamin D status was generally poor. During a median follow-up period of 2.9 (IQR, 2.1-3.9) years, 18 patients developed PTM. The incidence of PTM in this study was as high as 2.9 [95% CI, 0.2-4.8] /100 patient-years as a whole, consistent with previous reports (4, 9, 35-37). The significant association between AVD usage and a decreased incidence of PTM remained almost the same with several sensitivity analyses. Our preliminary results suggest a novel potential strategy to prevent PTM using a usual dose of AVDs with their well-known safety profiles, which are readily available and inexpensive.
KTRs are exposed to various kinds of risk factors for malignancy (9) . In addition to This study has several limitations. First, our results might be biased to some extent as is true with all observational studies.Second, residual confounding may exist although we tried to adjust rigorously for the observed factors using a PS-based approach. Third, we could not adjust for unobserved factors such as smoking status, genetic disposition and human papilloma virus infection. Since we did not administer the diet history questionnaire, dietary vitamin D may also remain a residual confounder. However, this is unlikely the case because we adjusted for serum 25(OH)D levels, which reflect dietary vitamin D intake if we take seasonality into account. Moreover, the estimated effect size of AVDs was similar in several sensitivity analyses, which suggests the robustness of our results. Another major limitation is limited statistical power. We could not show who would benefit most from 
